Acadian Asset Management
BLRX

Acadian Asset Management’s BioLineRX BLRX Stock Holding History

Acadian Asset Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-474
Closed -$32K – 2176
2020
Q2 		$32K Buy
+474
New +$32.4K ﹤0.01% 2023
2015
Q2 		– Sell
-115
Closed -$145K – 1365
2015
Q1 		$145K Buy
+115
New +$142K ﹤0.01% 971

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Acadian Asset Management's BLRX Position: Q3 2020 in Review

Acadian Asset Management sold out of BioLineRX (BLRX) in Q3 2020, closing a stake of 474 shares — an estimated $32K sold.

Acadian Asset Management first reported a position in BLRX in Q1 2015 and held it in 2 quarters. The position peaked at $145K in Q1 2015. 18 funds tracked by Wall St. Rank hold BLRX as of Q3 2020.

  • Acadian Asset Management reported no remaining BioLineRX position as of Q3 2020 after selling out during the quarter.
  • Acadian Asset Management sold 474 BioLineRX shares in Q3 2020, an estimated $32K.
  • Acadian Asset Management first reported a position in BioLineRX in Q1 2015 and held it in 2 quarters.
  • Acadian Asset Management's BioLineRX position peaked at $145K in Q1 2015.
  • 18 funds tracked by Wall St. Rank held BioLineRX as of Q3 2020.

Based on Acadian Asset Management's 13F filing for Q3 2020, filed 9 Nov 2020.